Dr. San Martin’s career has focused on guiding therapeutics from proof of concept through regulatory approval, with special emphasis on aligning late-stage development efforts with viable commercialization paths. He is the Senior Vice President and Head of Global Clinical Development at Ultragenyx. He leads the Development Team for Crysvita (burosumab-twza), the first drug approved to treat the rare, inherited disease of x-linked hypophosphatemia (XLH). While at Amgen he led two major development programs as Global Development Leader for Amgen’s Bone Therapeutic Area. He directed the anti-sclerostin antibody clinical program through the end of phase II, and prior to that, was responsible for development and approval of Prolia (denosumab) for the treatment of postmenopausal osteoporosis.

Prior to Amgen, he spent seven years at Eli Lilly working on phase IIIb and phase IV clinical trials to support the successful launch and medical affairs activities for Evista and Forteo. A thought leader, writer and researcher who is widely published in the field of bone research, Dr. San Martin has lectured extensively in the United States, Latin America, Canada, and Europe on topics such as the drug development process in bone diseases and women’s health. He received his medical degree from the University of Buenos Aires Medical School and completed his residence in internal medicine at CEMIC University of Buenos Aires. He is a member of the American Society of Bone Mineral Research.